Trials / Active Not Recruiting
Active Not RecruitingNCT06989788
A Study to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for Chronic Hepatitis B Virus Infection, in Healthy Adults
A Randomised, Double-blind, Placebo-controlled, Single Centre, Phase I Study to Evaluate the Safety, Reactogenicity and Immunogenicity of AstriVax' Investigational Therapeutic Hepatitis B Virus (HBV) Vaccine (AVX70371) in Healthy Adults Aged 18 to 40 Years
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (estimated)
- Sponsor
- AstriVax Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this first time in humans trial is to evaluate the safety, reactogenicity and immunogenicity of repeated administrations of AVX70371 in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AVX70371 | AstriVax Therapeutics' HBV immunotherapeutic |
| OTHER | Placebo | Placebo |
Timeline
- Start date
- 2025-05-06
- Primary completion
- 2026-08-31
- Completion
- 2026-08-31
- First posted
- 2025-05-25
- Last updated
- 2025-06-22
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT06989788. Inclusion in this directory is not an endorsement.